CluenexSynchrony Financial SYF
Synchrony Financial scores good on business quality (6.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Synchrony Financial does
Synchrony Financial provides consumer financing, issuing private label and co-branded credit cards through major retail and healthcare partners who pay them merchant fees and interest. The company is leaning into specialized verticals like veterinary care through recent partnerships like Vetspire to expand its CareCredit network.
- What it does best
Synchrony dominates retail private label credit through deeply embedded partner integrations. It achieves a 20.9% ROE, outperforming peers like Capital One at 9.3%, driven by captive merchant ecosystems that make switching costs painfully high for retailers.
- The main risk
Credit card default cycles and consumer delinquency spikes threaten net margins. With revenue dropping 2.8% recently, any wider economic squeeze directly hits its unsecured lending portfolio and compresses profitability.
Quality, check by check
Scored against its own industry, from company filings.
Net margin stands at 17.9% with a 20.9% ROE, showing healthy profitability on existing operations. The business converts scale into strong earnings efficiently.
Its economic moat relies on high switching costs across retail and health partners, supported by a solid 70th percentile ROE rank that proves strong capital returns within financial services.
Revenue growth is struggling at -2.8% annually, putting it in the bottom quartile of its sector at the 7th percentile and showing a clear fade compared to prior years.
Debt-to-equity sits at 0.9x with total debt at $15.2B, backed by steady operating cash flow of $9.7B. The balance sheet remains stable and adequately capitalized.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on SYF
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Synchrony Financial scores good on the Cluenex quality check (6.3 of 10), measured against its own industry. Profitability is strong, moat strong, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Oct 20, 2026, before the open.
See SYF today
- Today's verdict on SYF, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Synchrony Financial (SYF)”, https://cluenex.com/stocks/syf/, data as of Oct 10, 2026.